Celldex Therapeutics Completes Enrollment of Phase 2b Study

Celldex Therapeutics has completed patient enrollment for its phase 2b study of glembatumumab vedotin in patients with metastatic triple negative breast cancers that overexpress gpNMB.

Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, including breast cancer. Overexpression of gpNMB has been shown to promote the migration, invasion and metastasis of the disease. “We believe glemba holds significant promise as a potential new targeted treatment for patients with this devastating disease and look forward to topline data, likely in the second quarter of 2018,” said CEO Anthony Marucci.

Leave A Reply

Your email address will not be published.